Journal article
First experience of durable cytoreduction in chronic lymphoid leukemia with 177Lu-DOTATATE.
- Savovic T Nuclear Medicine Department and Molecular Imaging, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
- Prior JO Nuclear Medicine Department and Molecular Imaging, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
- Nicod-Lalonde M Nuclear Medicine Department and Molecular Imaging, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
- Bressoud A Medical Oncology, Clinique Bois-Cerf, Lausanne, Switzerland.
- Roux S Interal Medicine, Centre Médical du Bouveret, Bouveret, Switzerland.
- Schaefer N Nuclear Medicine Department and Molecular Imaging, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland. niklaus.schaefer@chuv.ch.
- Meyer M Nuclear Medicine Department and Molecular Imaging, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
- 2019-03-29
Published in:
- Medical oncology (Northwood, London, England). - 2019
117Lu-DOTATATE
Chronic lymphoid leukemia
Neuroendocrine tumor
PET/CT
PRRT
Aged
Antineoplastic Agents
Cytoreduction Surgical Procedures
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
Liver Neoplasms
Neuroendocrine Tumors
Octreotide
Organometallic Compounds
Treatment Outcome
English
This is the first described case of effective and durable cytoreduction after PRRT with 177Lu-DOTATATE in a 75-year-old female, with B cell chronic lymphoid leukemia, and well-differentiated metastatic neuroendocrine tumor.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1007/s12032-019-1266-0
- PMID 30919094
- Persistent URL
- https://sonar.ch/global/documents/246728
Statistics
Document views: 24
File downloads: